News | May 13, 2023
Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Subscribe To Our Newsletter & Stay Updated
